NCT01500148

Brief Summary

The purpose of this proof-of-concept study is to assess the relative safety and feasibility of the SJM Percutaneous Mitral Valve Repair (PMVr) Device.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2

participants targeted

Target at below P25 for phase_1

Timeline
Completed

Started Dec 2011

Shorter than P25 for phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2011

Completed
5 days until next milestone

First Submitted

Initial submission to the registry

December 6, 2011

Completed
22 days until next milestone

First Posted

Study publicly available on registry

December 28, 2011

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2012

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2012

Completed
Last Updated

February 4, 2019

Status Verified

February 1, 2019

Enrollment Period

6 months

First QC Date

December 6, 2011

Last Update Submit

February 1, 2019

Conditions

Keywords

Mitral Valve ProlapseMitral Valve DiseaseMitral Valve RegurgitationMitral Valve InsufficiencyMitral Valve IncompetencePercutaneous Mitral Valve RepairPosterior leaflet prolapseMitral valve degeneration

Outcome Measures

Primary Outcomes (1)

  • Device and Procedural Success

    The primary objective is to evaluate the technical feasibility and acute device deployment characteristics of the SJM PMVr Device. Technical feasibility and deployment characteristics will be defined as: * The ability of the delivery system to access the mitral valve * The ability of the device to capture mitral valve (MV) leaflet tissue * Ability to plicate MV leaflet tissue * The clip is able to be deployed in MV leaflet tissue * The delivery system is able to be removed.

    During the investigational procedure

Secondary Outcomes (1)

  • Quantification of SAEs reported that are unique to the investigational procedure

    Through 6 weeks post-implantation

Study Arms (1)

Intevention-PMVr Procedure

EXPERIMENTAL
Device: PMVr procedure (SJM Percutaneous Mitral Valve Repair (PMVr)

Interventions

A maximum of ten (10) subjects will receive a percutaneous mitral valve clip procedure.

Intevention-PMVr Procedure

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject has symptomatic or asymptomatic moderate (2+) or severe (3-4+) mitral regurgitation.
  • Subject has an ejection fraction (EF) ≥ 30%.
  • Subject is of legal age (≥18 years old).
  • Subject is planned to undergo surgical repair or replacement of the mitral valve for symptomatic or asymptomatic posterior leaflet mitral prolapse.

You may not qualify if:

  • Subject requires a complex mitral valve repair or has isolated anterior prolapse.
  • Subject has mitral valve stenosis in which the annulus opening is \<10mm. Subject has valve disease other than mitral which requires surgical intervention.
  • Subject requires a concomitant procedure.
  • Subject has a pre-existing prosthetic valve in any position.
  • Subject had stenting or PCI within 6 months before the planned procedure, or is anticipated to require stenting or PCI within 6 months post-procedure.
  • Subject has calcification of the mitral leaflets or annulus which in the medical opinion of the surgical investigator would limit repair and /or implantation of the investigational device.
  • Subject has renal insufficiency or is on chronic dialysis.
  • Subject has had a cerebral vascular accident (CVA) or transient ischemic attack (TIA) within the past 6 months.
  • Subject has a history of endocarditis or has active endocarditis.
  • Subject has a history of autoimmune disease.
  • Subject has significant known carotid artery disease.
  • Subject has an aorto-mitral angle of \<110 degrees.
  • Subject has hypertrophic obstructive cardiomyopathy (HOCM's Disease).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Papworth Hospital

Cambridge, United Kingdom

Location

MeSH Terms

Conditions

Mitral Valve ProlapseMitral Valve Insufficiency

Condition Hierarchy (Ancestors)

Heart Valve ProlapseHeart Valve DiseasesHeart DiseasesCardiovascular Diseases

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 6, 2011

First Posted

December 28, 2011

Study Start

December 1, 2011

Primary Completion

June 1, 2012

Study Completion

August 1, 2012

Last Updated

February 4, 2019

Record last verified: 2019-02

Locations